United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Purchases 424,796 Shares of Gilead Sciences, Inc. $GILD

Key Points

• United Super Pty Ltd sharply increased its Gilead Sciences stake by 1,679% in the fourth quarter, adding 424,796 shares to end with 450,096 shares worth about $55.2 million.
• Insiders have been selling shares recently, including CEO Daniel Patrick O’Day and insider Johanna Mercier, with total insider sales of 53,000 shares over the last 90 days.
• Gilead reported better-than-expected Q1 results with EPS of $2.03 on revenue of $6.96 billion, and analysts remain broadly positive with an average Moderate Buy rating and a $156.93 price target.

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund grew its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1,679.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 450,096 shares of the biopharmaceutical company's stock after buying an additional 424,796 shares during the period. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund's holdings in Gilead Sciences were worth $55,245,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Gilead Sciences by 2.6% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 91,149 shares of the biopharmaceutical company's stock valued at $11,188,000 after buying an additional 2,327 shares in the last quarter. Jupiter Asset Management Ltd. raised its position in shares of Gilead Sciences by 63.5% in the 4th quarter. Jupiter Asset Management Ltd. now owns 14,910 shares of the biopharmaceutical company's stock valued at $1,830,000 after purchasing an additional 5,790 shares during the last quarter. Moors & Cabot Inc. raised its position in shares of Gilead Sciences by 4.9% in the 4th quarter. Moors & Cabot Inc. now owns 20,407 shares of the biopharmaceutical company's stock valued at $2,505,000 after purchasing an additional 946 shares during the last quarter. EagleClaw Capital Managment LLC raised its position in shares of Gilead Sciences by 9.3% in the 4th quarter. EagleClaw Capital Managment LLC now owns 9,390 shares of the biopharmaceutical company's stock valued at $1,153,000 after purchasing an additional 800 shares during the last quarter. Finally, Intech Investment Management LLC raised its position in shares of Gilead Sciences by 19.9% in the 4th quarter. Intech Investment Management LLC now owns 293,214 shares of the biopharmaceutical company's stock valued at $35,989,000 after purchasing an additional 48,622 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction on Friday, May 15th. The shares were sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the completion of the sale, the insider owned 125,779 shares of the company's stock, valued at $16,513,524.91. This represents a 18.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the sale, the chief executive officer directly owned 632,567 shares of the company's stock, valued at approximately $81,702,353.72. This represents a 1.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 53,000 shares of company stock valued at $7,075,670 over the last 90 days. 0.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

GILD has been the subject of several research reports. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Gilead Sciences from $135.00 to $155.00 and gave the stock a "buy" rating in a research note on Wednesday, February 11th. Wolfe Research lifted their price objective on shares of Gilead Sciences from $155.00 to $170.00 and gave the stock an "outperform" rating in a research note on Thursday, February 12th. Jefferies Financial Group initiated coverage on shares of Gilead Sciences in a research note on Tuesday, March 10th. They set a "buy" rating and a $180.00 price objective for the company. Leerink Partners lowered their price objective on shares of Gilead Sciences from $148.00 to $146.00 in a research note on Friday, May 8th. Finally, Maxim Group upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $165.00 price objective for the company in a research note on Wednesday, May 20th. Twenty-five equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $156.93.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $136.22 on Friday. The firm has a market cap of $169.13 billion, a PE ratio of 18.56 and a beta of 0.31. The firm has a fifty day moving average of $135.43 and a 200 day moving average of $134.08. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. Gilead Sciences, Inc. has a one year low of $104.46 and a one year high of $157.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping the consensus estimate of $1.91 by $0.12. The company had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm's revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050--0.650 EPS. As a group, research analysts predict that Gilead Sciences, Inc. will post -0.79 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be issued a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences's payout ratio is presently 44.69%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.